Skip to content. | Skip to navigation

National Cancer Institute U.S. National Institutes of Health www.cancer.gov

Navigation

Personal tools

You are here: Home / Biomarkers / APOA1

APOA1

Basics

Aliases:
This biomarker is also known as:
  • Apolipoprotein A-I,
  • MGC117399,
  • Apo-AI,
  • apolipoprotein A-I,
  • Apolipoprotein A1,
  • ApoA-I,

View in BioMuta

Description…

APOA1, a secreted protein belonging to the apolipoprotein A1/A4/E family, participates in the reverse transport of cholesterol from tissues to the liver for excretion by promoting cholesterol efflux from tissues and by acting as a cofactor for the lecithin cholesterol acyltransferase (LCAT). As part of the SPAP complex, APOA1 activates spermatozoa motility. This protein is a major protein of plasma HDL and is also found in chylomicrons. It is synthesized in the liver and small intestine. Defects in APOA1 are a cause of several diseases: 1) high density lipoprotein deficiency type 2 (HDLD2), also known as familial hypoalphalipoproteinemia, for which inheritance is autosomal dominant; 2) the low HDL levels observed in high density lipoprotein deficiency type 1 (HDLD1), also known as analphalipoproteinemia or Tangier disease (TGD), a recessive disorder characterized by the absence of plasma HDL, accumulation of cholesteryl esters, premature coronary artery disease, hepatosplenomegaly, recurrent peripheral neuropathy and progressive muscle wasting and weakness; 3) amyloid polyneuropathy-nephropathy Iowa type (AMYLIOWA), also known as amyloidosis van Allen type or familial amyloid polyneuropathy type III, a hereditary generalized amyloidosis due to deposition of amyloid mainly constituted by apolipoprotein A1; 4) amyloidosis type 8 (AMYL8), also known as systemic non-neuropathic amyloidosis or Ostertag-type amyloidosis, a hereditary generalized amyloidosis due to deposition of apolipoprotein A1, fibrinogen and lysozyme amyloids.

Attributes

QA State: Curated
Type: Protein
Short Name:
HGNC Name: APOA1

Datasets

There are no datasets associated with this biomarker.

Organs

The following organs have data associated with this biomarker…

Ovary

Attributes

Phase: Three
QA State: Curated

Overview

In laboratory testing, APOA1, in a panel (including transthyretin, transferrin, and CA125) has been shown to be a highly sensitive (96%) predictor of early stage ovarian cancer and endometrial cancer.

Performance Comment

Of the 28 ovarian cancer biomarkers tested in prediagnostic specimens, from the PLCO, CA125 remains the single best biomarker for ovarian cancer and has its strongest signal within six months of diagnosis. APOA1 alone was not a strong predictor.

Studies

This biomarker is currently being annotated or is under review. You must be logged in or do not have permission to view any additional information. Contact Heather Kincaid at heather.kincaid@jpl.nasa.gov if you should have access to this biomarker.

Publications

No associated publications found.

New Funding Opportunity: Biomarker Development Laboratories for the Early Detection Network: Applications Due May 23

Update: Pre-application webinar information now available.

The National Cancer Institute's Division of Cancer Prevention has released a new funding opportunity to solicit organ-specific applications for Biomarker Developmental Laboratories (BDLs), one of the four scientific units of the recently funded Early Detection Research Network (EDRN). The EDRN is a national infrastructure funded to discover, develop, and validate biomarkers for risk assessment, detection, and molecular diagnosis and prognosis of early cancer. BDLs are responsible for the discovery, development, characterization, and testing of new, or the refinement of existing, biomarkers and biomarker assays for risk assessment, detection, and molecular diagnosis and prognosis of cancers.

The existing BDLs are primarily focused on ovary and gastrointestinal cancers. The proposed BDLs (to be supported under this funding opportunity) should be focused on one or more of the following cancers: breast, prostate and other genitourinary organs, or lung. In addition, cancers with rapidly rising incidence rates, e.g., endometrial, hepatocellular, kidney, thyroid, oropharyngeal cancers, and/or cancers with unique etiology, e.g., mesothelioma, will be considered.

The newly funded units of the Early Detection Research Network will be announced later in April. Successful applicants have already been notified. Those researchers who were not successful during the last round of applications are encouraged to apply to this opportunity.